Boston Scientific, Inc. BSX recently announced receiving the FDA approval for the latest-generation WATCHMAN FLX Pro Left Atrial Appendage Closure (LAAC) Device. The latest device is intended to ...

Add Yahoo as a preferred source to see more of our stories on Google. Boston Scientific’s Watchman FLX Pro device, the latest version of its left atrial appendage closure system, was approved by the ...

After the FDA said last year it would keep a closer eye on the potential complications of a type of permanent heart plug designed to cut the risk of stroke, Boston Scientific has put forward ...

Boston Scientific has obtained an FDA green light for the latest version of its Watchman heart implant, designed to help lower the risk of stroke in patients with atrial fibrillation. Compared to its ...

Boston Scientific Corporation BSX recently announced favorable three-year primary endpoint data from the OPTION global clinical trial for its WATCHMAN FLX Left Atrial Appendage Closure (“LAAC”) device ...

On Saturday, Boston Scientific Corporation (NYSE:BSX) unveiled three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX Left Atrial Appendage Closure (LAAC) Device ...

MARLBOROUGH, Mass., Sept. 6, 2023 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received U.S. Food and Drug Administration approval for the latest-generation ...

Shares in Boston Scientific tumbled to their lowest level in more than two years on Monday after the medical device maker shared what should have been encouraging new data for its Watchman heart ...

PHOENIX — Abrazo Arizona Heart Hospital in Phoenix last week became the first health center in the state to implant a new device designed to reduce stroke risk. The hospital, which is located on ...

MARLBOROUGH, Mass. and NEW ORLEANS, March 28, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that the CHAMPION-AF global clinical trial met all primary and secondary ...

Editor's note: This is the second of a two-part series on the Boston Scientific Investor Day presentation. While Farapulse owned the spotlight at Boston Scientific's investor event last week, that ...